There is an unmet medical need to develop novel treatment modalities for patients with triple negative breast cancer (TNBC), an aggressive breast cancer subtyp. characterized by poor survival rates. The immunogenic nature of TNBC has prompted researchers to exploit a type of adoptive cell therapy called chimeric antigen receptor (CAR)-T cell therapy for the treatment of TNBC. Strategies to address the inherent challenges associated with CAR-T cell therapy in solid tumors and emerging targets and ongoing clinical trials for CAR-T cell therapy in TNBC are discussed in this review.

One alternative to discovering novel drugs is to repurpose existing ones. In this study, Werfel and colleagues performed a phenome-wide association study (PheWAS) and identified clinical manifestations correlating with a thromboxane A2-prostanoid receptor (TPr) single nucleotide polymorphism associated with cancer metastasis in several cancer types. CPI211, a TPr inhibitor used in cardiovascular diseases, inhibited TPr in murine models and blocked spontaneous...

You do not currently have access to this content.